Camlin Fine Sciences Limited
NSE: CAMLINFINESpecialty Chemicals
Share price
₹89.98
+1.28% close of 9 Oct 2026
Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 7 Oct 2026, the close above is 9 Oct 2026.
Business score
How strong the business is, in one number. The parts behind it are in Pro.
44
out of 100 · worked out 9 Oct 2026
Your ratios
The numbers you want to see first. Tap Edit to change them.
Market cap
₹1,710 Cr
P/E ratio
—
P/B ratio
1.7
ROCE
4.8%
ROE
3.7%
Dividend yield
0.0%
Price & valuation chart
How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.
Answers
Simple answers to the questions investors ask most, from the company's own numbers.
How fast it has been growing
Sales grew 9.3% over the past year, and 20.4% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales slipped from 10.0% to 4.7% over the last four years.
Whether it grew faster than its sector
It grew 20.4% a year against a sector median of 10.2% — 10.2 percentage points faster.
Room to re-rate, or risk of de-rating
It has no earnings, so there is no price-to-earnings to compare.
Whether growth justifies the valuation
It has no earnings to weigh the price against.
| Profit growth | Price per ₹1 profit | Per 1% growth | |
|---|---|---|---|
| Camlin Fine Sciences Limited — this one | -14%/yr | — | — |
| Pidilite Industries | 25%/yr | 57.1× | ₹2.3 |
| Gujarat Fluorochemicals Limited | -24%/yr | 79.7× | — |
| Navin Fluorine International Limited | 21%/yr | 52.6× | ₹2.5 |
| Aether Industries Limited | 20%/yr | 96.9× | ₹4.8 |
| Deepak Nitrite Limited | -13%/yr | 27.6× | — |
Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
How it compares with its peers
Against companies the exchange files under the same label (Specialty Chemicals), it ranks 61 of 73 on returns, 10 of 72 on growth, 58 of 73 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
What makes it hard to beat — and is that still true?
No durable advantage shows in the numbers: it earns 4.8% on capital, ahead of 16% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
Whether its growth pays for itself
No — Over the last five years it made ₹440 crore of cash from the business but spent ₹517 crore on plant and equipment, ₹77 crore more than it made; the gap was from lenders and shareholders. And the profit is real: of every 100 rupees it reported over 12 years, about 3309 arrived as cash — well above the profit; depreciation and interest are the reason, not a windfall. Its cash comes back faster than it used to: it went from being waiting 40 days for its cash to waiting 23 days for its cash.
Profit reality check
Is the profit real cash? Simple checks on the accounts. Facts only, not advice.
5 of 10 checks clear · 50%
Latest result · Q1 FY27
What the last results showed. Whether management kept its word is in Pro.
Revenue rose 23% but the quarter ran to a ₹34 crore loss, and full-year margin guidance was cut to 10-12%
Announced 11 Aug 2026 · Consolidated · Unaudited
Revenue
₹520 Cr
Revenue vs last year
+22.6%
Revenue vs last quarter
+22.3%
Net profit
-₹34 Cr
Profit vs last quarter
-139.1%
Net margin
-6.5%
EPS
₹-1.65
Earnings call transcript · 11 Aug 2026
Checklist before you investPRO
Points for and against, in one list.
Key numbers & peers
The main numbers grouped by topic, and how the company compares with similar ones.
Price
- Market cap
- ₹1,710 Cr
- Prev close
- ₹89.98
- 52w High
- ₹205
- 52w Low
- ₹88.2
- Enterprise value
- ₹2,277 Cr
- Beta
- 1.6
- Price CAGR 1y
- -52.0%
- Price CAGR 3y
- -16.0%
- Price CAGR 5y
- -13.0%
- Price CAGR 10y
- 1.0%
Ratios
- Return on assets
- 1.0%
- PEG ratio
- -4.0
- P/E ratio
- —
- P/B ratio
- 1.7
- EV / EBITDA
- 27.1
- Industry P/E
- 31.9
- ROCE
- 4.8%
- ROCE 5y average
- 9.0%
- ROE
- 3.7%
- Debt / Equity
- 0.7
- Interest coverage
- 1.3
- Dividend yield
- 0.0%
- ROE 3y average
- -7.0%
- ROE last year
- 4.0%
Annual P&L
- Annual revenue
- ₹1,723 Cr
- Annual profit
- ₹24 Cr
- Operating margin
- 7.0%
- Net profit margin
- 1.4%
- EBITDA margin
- 6.8%
- Sales growth 3y
- 0.8%
- Sales growth 5y
- 7.7%
- Profit growth 3y
- -14.0%
- Profit growth 5y
- -6.0%
- EPS
- ₹1.4
- Sales growth TTM
- 9.0%
- Profit growth TTM
- -139.0%
- Dividend payout
- 0.0%
Quarter P&L
- Sales latest quarter
- ₹520 Cr
- Profit latest quarter
- -₹34 Cr
- YoY quarterly sales growth
- 27.5%
- YoY quarterly profit growth
- —
- OPM latest quarter
- 1.8%
Balance Sheet
- Book Value
- ₹54.8
- Face Value
- ₹1.0
- Total debt
- ₹720 Cr
- Total cash
- ₹153 Cr
- Borrowings
- ₹720 Cr
- Reserves / Equity
- 53.8
Cash Flow
- Operating cash flow
- ₹82 Cr
- Free cash flow
- ₹25 Cr
- FCF yield
- -3.4%
- Net cash flow
- ₹4 Cr
Shareholding
- Promoter holding
- 48.0%
- FII holding
- 0.9%
- DII holding
- 5.4%
- Public holding
- 45.6%
Peer comparison
| Company | Price ₹ | P/E | Mkt cap ₹ Cr | Div yield % | Profit qtr ₹ Cr | Profit var % | Sales qtr ₹ Cr | Sales var % | ROCE % |
|---|---|---|---|---|---|---|---|---|---|
| Pidilite Inds. | 1,488.50 | 57.3 | 1,51,685 | 0.77 | 883.5 | 28.2 | 4,551.6 | 21.3 | 31.0 |
| Gujarat Fluoroch | 4,555.90 | 80.8 | 49,893 | 0.07 | 219.0 | 21.4 | 1,588.0 | 24.0 | 9.6 |
| Navin Fluo.Intl. | 8,490.00 | 54.8 | 43,545 | 0.18 | 243.3 | 107.7 | 1,045.1 | 44.1 | 21.0 |
| Aether Industri. | 1,787.60 | 98.9 | 23,724 | 0.00 | 62.8 | 28.0 | 326.6 | 27.3 | 11.9 |
| Deepak Nitrite | 1,553.90 | 26.8 | 21,198 | 0.48 | 345.0 | 207.5 | 2,577.6 | 36.4 | 11.4 |
| Aarti Industries | 491.25 | 34.2 | 17,842 | 0.20 | 155.0 | 256.5 | 2,387.0 | 42.5 | 6.9 |
| Atul | 5,999.50 | 22.2 | 17,660 | 0.50 | 253.9 | 92.0 | 1,848.0 | 25.0 | 14.9 |
| Camlin Fine | 94.52 | 1,817 | 0.00 | -33.6 | -606.8 | 519.9 | 27.5 | 4.8 | |
| Median | 367.30 | 29.7 | 1,098 | 0.24 | 13.5 | 52.2 | 175.3 | 26.4 | 13.8 |
Competes with: Aarti Industries Limited, Aether Industries Limited, Atul Limited, BASF India Limited, Deepak Nitrite Limited, Gujarat Fluorochemicals Limited, Navin Fluorine International Limited, Pidilite Industries
Quarterly results
Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.
| Line item | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 420 | 406 | 386 | 377 | 381 | 417 | 431 | 432 | 408 | 460 | 441 | 425 | 520 |
| Expenses | 381 | 381 | 363 | 345 | 352 | 366 | 375 | 370 | 387 | 427 | 420 | 404 | 511 |
| Material Cost | 195 | 226 | 209 | 268 | 121 | 312 | |||||||
| Change in Inventories | 18 | -6.39 | 5.77 | -33 | 80 | -12 | |||||||
| Purchases of Stock-in-Trade | 2.36 | 17 | 32 | 14 | 18 | 5.82 | |||||||
| Employee Cost | 50 | 60 | 60 | 64 | 66 | 73 | |||||||
| Other Expenses | 113 | 108 | 119 | 123 | 119 | 131 | |||||||
| Operating Profit | 39 | 25 | 23 | 31 | 29 | 52 | 56 | 62 | 20 | 33 | 21 | 21 | 9 |
| OPM % | 9.23 | 6.19 | 6.05 | 8.36 | 7.59 | 12 | 13 | 14 | 4.98 | 7.19 | 4.73 | 4.99 | 1.79 |
| Other Income | 6 | 2 | 2 | -96 | -15 | -151 | -8 | -22 | -0 | -4 | -24 | 103 | -10 |
| Exceptional items (within Other Income) | -5.59 | 0 | 0 | -18 | -7.95 | -11 | |||||||
| Interest | 10 | 20 | 14 | 16 | 23 | 26 | 34 | 15 | 15 | 19 | 17 | 23 | 14 |
| Depreciation | 19 | 19 | 21 | 13 | 15 | 17 | 14 | 17 | 16 | 19 | 16 | 21 | 19 |
| Profit before tax | 16 | -12 | -10 | -94 | -23 | -142 | -0 | 8 | -11 | -9 | -37 | 80 | -34 |
| Tax % | 25 | 72 | 47 | -13 | 48 | -18 | 2,164 | 98 | -0 | 65 | -0 | -8 | -1 |
| Net Profit | 12 | -21 | -14 | -82 | -35 | -116 | -7 | 0 | -11 | -15 | -37 | 86 | -34 |
| EPS in Rs | 0.83 | -1.03 | -0.63 | -4.11 | -1.81 | -5.33 | -0.22 | -0.04 | -0.53 | -0.76 | -1.89 | 4.59 | -1.65 |
| Diluted EPS in Rs | -0.04 | -0.52 | -0.76 | -1.91 | 4.54 | -1.65 |
Profit & loss
Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.
| Line item | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 558 | 489 | 534 | 721 | 892 | 1,049 | 1,187 | 1,412 | 1,682 | 1,454 | 1,629 | 1,723 | 1,845 |
| Expenses | 474 | 397 | 502 | 705 | 819 | 914 | 1,000 | 1,254 | 1,471 | 1,284 | 1,402 | 1,605 | 1,761 |
| Material Cost | 786 | 823 | |||||||||||
| Change in Inventories | -55 | 11 | |||||||||||
| Purchases of Stock-in-Trade | 118 | 89 | |||||||||||
| Employee Cost | 192 | 244 | |||||||||||
| Other Expenses | 417 | 450 | |||||||||||
| Operating Profit | 84 | 92 | 32 | 16 | 73 | 135 | 187 | 158 | 211 | 170 | 227 | 118 | 84 |
| OPM % | 15 | 19 | 6 | 2.20 | 8 | 13 | 16 | 11 | 13 | 12 | 14 | 7 | 4.60 |
| Other Income | 9 | -1 | 14 | 12 | 14 | 3 | 5 | 33 | -4 | -142 | -218 | 59 | 64 |
| Exceptional items (within Other Income) | -9.82 | -25 | |||||||||||
| Interest | 24 | 24 | 31 | 32 | 41 | 48 | 42 | 41 | 64 | 70 | 107 | 83 | 73 |
| Depreciation | 16 | 17 | 22 | 27 | 29 | 33 | 44 | 56 | 63 | 56 | 61 | 71 | 75 |
| Profit before tax | 53 | 50 | -6 | -31 | 17 | 58 | 105 | 94 | 80 | -99 | -158 | 23 | -0 |
| Tax % | -4 | 28 | -26 | -22 | 82 | 49 | 38 | 36 | 50 | 6 | -0 | -2 | |
| Net Profit | 55 | 36 | -4 | -24 | 3 | 30 | 65 | 60 | 40 | -105 | -158 | 24 | 1 |
| EPS in Rs | 5.11 | 3.30 | -0.96 | -2.18 | 0.04 | 2.23 | 3.56 | 3.45 | 2.96 | -4.94 | -7.40 | 1.44 | 0.29 |
| Diluted EPS in Rs | -7.94 | 1.42 | |||||||||||
| Dividend Payout % | 8 | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Compounded growth
Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.
Compounded sales growth
- 10 years
- 13%
- 5 years
- 8%
- 3 years
- 1%
- TTM
- 9%
Compounded profit growth
- 10 years
- -1%
- 5 years
- -6%
- 3 years
- -14%
- TTM
- -139%
Stock price CAGR
- 10 years
- 1%
- 5 years
- -13%
- 3 years
- -16%
- 1 year
- -52%
Return on equity
- 10 years
- -1%
- 5 years
- -2%
- 3 years
- -7%
- Last year
- 4%
Balance sheet
What the company owns and what it owes, at the end of each year. ₹ crore.
| Line item | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 12 | 12 | 12 | 13 | 16 | 16 | 17 | 19 | 19 |
| Reserves | 125 | 167 | 202 | 359 | 359 | 391 | 631 | 732 | 804 | 848 | 883 | 1,022 |
| Borrowings | 160 | 180 | 331 | 373 | 461 | 539 | 550 | 646 | 801 | 683 | 652 | 720 |
| Other Liabilities | 131 | 123 | 126 | 273 | 255 | 290 | 282 | 396 | 425 | 424 | 467 | 559 |
| Minority Interest | -27 | -40 | ||||||||||
| Total Liabilities | 426 | 479 | 669 | 1,016 | 1,087 | 1,232 | 1,475 | 1,790 | 2,045 | 1,972 | 2,020 | 2,320 |
| Fixed Assets | 106 | 140 | 201 | 278 | 272 | 306 | 584 | 601 | 858 | 816 | 704 | 887 |
| CWIP | 3 | 25 | 8 | 14 | 59 | 179 | 24 | 215 | 43 | 46 | 10 | 33 |
| Investments | 1 | 1 | 19 | 115 | 11 | 7 | 7 | 7 | 8 | 8 | 61 | 30 |
| Other Assets | 316 | 313 | 442 | 609 | 745 | 740 | 861 | 966 | 1,136 | 1,102 | 1,246 | 1,370 |
| Total Assets | 426 | 479 | 669 | 1,016 | 1,087 | 1,232 | 1,475 | 1,790 | 2,045 | 1,972 | 2,024 | 2,324 |
Cash flows
Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.
| Line item | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 46 | 72 | -9 | -15 | -9 | 86 | 117 | 145 | 51 | 139 | 23 | 82 |
| Cash from Investing Activity | -26 | -66 | -70 | -149 | -2 | -90 | -133 | -249 | -125 | -66 | -75 | -53 |
| Cash from Financing Activity | -15 | -7 | 91 | 182 | 26 | 3 | 39 | 136 | 60 | -86 | 76 | -25 |
| Net Cash Flow | 4 | -1 | 13 | 18 | 15 | -1 | 23 | 32 | -14 | -13 | 24 | 4 |
| Free Cash Flow | 19 | 5 | -39 | -34 | -78 | -48 | 34 | -68 | -93 | 79 | -19 | 24 |
Ratios
How fast customers pay, how long stock sits, and how well capital earns — year by year.
| Line item | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 74 | 56 | 99 | 104 | 86 | 88 | 83 | 77 | 66 | 72 | 74 | 79 |
| Inventory Days | 184 | 311 | 277 | 207 | 219 | 204 | 200 | 178 | 255 | 256 | 234 | 199 |
| Days Payable | 144 | 171 | 110 | 154 | 127 | 119 | 99 | 112 | 129 | 154 | 180 | 200 |
| Cash Conversion Cycle | 114 | 196 | 266 | 157 | 178 | 173 | 184 | 143 | 192 | 174 | 127 | 78 |
| Working Capital Days | 12 | 1 | -6 | 19 | 43 | 22 | 55 | 40 | 42 | 51 | 33 | 23 |
| ROCE % | 28 | 24 | 5 | 0 | 7 | 11 | 13 | 10 | 10 | 8 | 12 | 5 |
Price trend
The price as a Renko brick chart: small moves drop out so the bigger path stands out.
Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.
Open interestPRO
Where option traders are positioned on this stock.
Industry numbers
The numbers that matter most in this industry, from the company's own filings.
1 when an audit qualification is filed as repetitive
0.00flag
2026-03-31
the company's own unlisted debt securities in default at period end
0.00cr
2026-06-30
the company's own loans / revolving facilities in default at period end (standalone filing)
0.00cr
2026-06-30
net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash
567inr_cr
2026-03-31
guarantees / comfort given for promoter, promoter group, directors and KMP
0.00cr
2026-03-31
loans outstanding to promoter, promoter group, directors and KMP (governance filing)
0.00cr
2026-03-31
security given for the borrowing of promoter, promoter group, directors and KMP
0.00cr
2026-03-31
FY revenue / permanent employees + workers, same basis (calc)
1,24,32,021inr
2026-03-31
News
News and filings about Camlin Fine Sciences Limited. Open one to see why it matters.
No recent news for this company.
Supply chain
Who it buys from, sells to and competes with — as recorded in our map of company links.
Competes with
Uses as raw material
- Catechol
- Guaiacol
- Phenol (feedstock for catechol/hydroquinone diphenols)
Depends on the price of
- Crude Oil Brent
Sells to
- Lockheed Martin Advanced Energy Storage · Specialty chemical for energy storage (preferred supply agreement)
About
What the company is, from our own records: where it sits, where it makes things, and what it is made of.
- Sector
- Chemicals
- Industry
- Specialty Chemicals
- Classification
- Chemicals › Specialty Chemicals
- ISIN
- INE052I01032
Plants
- Dahej SEZ Facility for Diphenols · Dahej, Gujarat
- Dahej SEZ Facility for Vanillin · Dahej, Gujarat
- Khopoli Facility · Khalapur/Khopoli, Maharashtra
- Mahad Facility · Mahad, Maharashtra
- Ningbo Wanglong Facility
- Ravenna (Borregaard Italia) Facility
- Tarapur Facility · Tarapur, Maharashtra
News impact
Big market events that reach Camlin Fine Sciences Limited, and how the effect spreads.
23 Sept, 07:38 IST · Market event · medium impact
India starts anti-dumping probe into Chinese Glycine imports
India is probing cheap Chinese glycine imports, which could help home chemical makers later but may raise costs for food, drug and farm buyers if an import tax follows.
Who it hits first
- India's trade investigator (DGTR, the body that checks unfair imports) opened a probe into cheap glycine, a simple chemical used in food, drugs and farm sprays, arriving from China.
- If the probe finds harm to local makers, India can add an import tax (anti-dumping duty) that makes Chinese glycine costlier and helps home producers sell more.
- No listed glycine maker is named in the evidence, so any stock lift today is hope of future protection, while buyers of glycine could later pay more.
Who may gain
- Indian glycine and nearby specialty makers, if a duty lifts local prices (no single listed maker confirmed in the pack)
- Farm-chemical sellers such as PI Industries and GSP Crop, if protection spreads to agro inputs
Along the supply chain
Downstream
Indian food, drug and farm-spray makers that buy glycine could face higher input costs if cheap Chinese supply is taxed.
Upstream
Chinese glycine exporters face the probe; if a duty follows, their shipments to India shrink.
Where demand moves
Business
No extra orders yet — the probe only starts the case; real business gain comes months later if a duty curbs Chinese supply and buyers switch to home makers.
Capital
No fresh funds flow; investors may bid up chemical shares on protection hopes, but cash gains arrive only if duties lift prices and profits.
How it spreads across sectors
Chemicals
Small positive mood for home makers on protection hopes; real gains only if a duty lands.
Pharma
Mild cost worry since glycine feeds drugs; dearer supply would squeeze pill makers later.
Textiles
Negligible near-term link; fibre makers watch only for broader China-duty mood.
A pattern seen before
Cascade chain
- DGTR probes Chinese glycine dumping → possible import duty
- Duty curbs cheap imports → domestic glycine prices firm
- Chemical makers gain share → pharma and textile buyers face higher costs
Pattern name
China Cascade
Patterns
- China Cascade
Sectors queried
- Pharma
- Textiles
When it plays out
Immediate
1–7 days: chemical shares drift on protection hopes with no order change.
Medium term
1–6 months: probe findings decide any duty; only then do prices, orders and margins move.
Short term
1–4 weeks: filings and hearing news set expectations; buyers watch for price hints.
Dividends, splits & big trades
Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.
Dividends
| 28 Jul 2016 | unspecified | ₹0.45 |
|---|---|---|
| 27 Jul 2015 | unspecified | ₹0.45 |
Splits, bonuses & buybacks
- daily-prices repair: 8 rows from NSE's archive (replace 1, delete 0, insert 7), 2016-10-30..2026-02-01 (docs/flat_day_repair.md)1× · 30 Oct 2016
Insider trades
| Disclosed | Who | Type | Shares | Value ₹ Cr |
|---|---|---|---|---|
| 28 Sep 2026 | Cyrille Damany · Other | SELL | 10,00,000 | 9.75 |
| 10 Apr 2026 | Ashish Subhash Dandekar · Director | EQUITY SHARES | 8,37,36,000 | — |
Documents
Annual reports, results presentations and earnings calls, straight from the source.
- Earnings call · Q1FY2711 Aug 2026
- Annual report · 2025-2618 Jul 2026
- Results presentation30 Jun 2026
- Earnings call · Q4FY2626 May 2026
- Earnings call · Q3FY2613 Feb 2026
Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.